Preventing recurrent depression: Long-term treatment for major depressive disorder

Journal of Clinical Psychiatry

Volumn 68, Issue 4, 2007, Pages 619-630

  Dunner, David L ^a,b   Blier, Pierre ^c,d   Keller, Martin B ^e   Pollack, Mark H ^f   Thase, Michael E ^g   Zajecka, John M ^h  

^a Center for Anxiety and Depression   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d ROYAL OTTAWA HOSPITAL   (Canada)

^e BROWN UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CITALOPRAM; DESIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; LITHIUM CARBONATE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ATYPICAL DEPRESSION; COGNITIVE THERAPY; COMORBIDITY; DRUG DOSE INCREASE; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MENTAL STRESS; PATIENT ATTITUDE; PHOTOTHERAPY; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOTHERAPY; PULMONARY HYPERTENSION; RECURRENT DISEASE; REMISSION; REVIEW; SEASONAL AFFECTIVE DISORDER; SUBSTANCE ABUSE; TACHYPHYLAXIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 34247529860     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0420     Document Type: Review

References (118)

1. Keller MB. The long-term treatment of major depression. J Clin Psychiatry 1999;60(suppl 17)41-45
2. Loonen AJ, Peer PG, Zwanikken GJ. Continuation and maintenance therapy with antidepressive agents: meta-analysis of research. Pharm Weekbl Sci 1991;13:167-175
3. Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000;61:851-857
4. Simon JS, Aquiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res2004;38:249-257
5. Harrison W, Rabkin J, Stewart JW, et al. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 1986;47:346-349
6. Scott J, Teasdale JD, Paykel ES, et al. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry 2000;177:440-446
7. Klein DN, Santiago NJ, Vivian D, et al. Cognitive-Behavioral Analysis System of Psychotherapy as a maintenance treatment for chronic depression. J Consult Clin Psychol 2004;72:681-688
8. Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy. Arch Gen Psychiatry 1998;55:816-820
9. Fava GA, Ruini S, Rafanelli C, et al. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004;161:1872-1876
10. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998;44:348-360
11. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988;3:69-76
12. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-195
13. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-222
14. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-188
15. Feiger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999;14:19-28
16. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(suppl 5):28-34
17. Hirschfeld RM. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994;55(12, suppl):61-69
18. Karp JF, Buysse DJ, Houck PR, et al. Relationship of variability in residual symptoms with recurrence of major depressive disorder during maintenance treatment. Am J Psychiatry 2004;161:1877-1884
19. Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 2003;64(suppl 15):13-17
20. Thase ME. Achieving remission and manaaing relapse in depression. J Clin Psychiatry 2003;64(suppl 18):3-7
21. Kennedy N, Foy K. The impact of residual symptoms on outcome of major depression. Curr Psychiatry Res 2005;7:441-146
22. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108
23. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-1504
24. Simons AD, Angell KL, Monroe SM, et al. Cognition and life stress in depression: cognitive factors and the definition, rating, and generation of negative life events. J Abnorm Psychol 1993;102:584-591
25. Bebbington PE, Brugha T, MacCarthy B, et al. The Camberwell Collaborative Depression Study, 1: depressed probands: adversity and the form of depression. Br J Psychiatry 1988;152:754-765
26. Petersen T, Iosifescu DV, Papakostas GI, et al. Clinical characteristics of depressed patients with comorbid diabetes mellitus. Int Clin Psychopharmacol 2006;21:43-47
27. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003;54:227-240
28. Iosifescu DV, Bankier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep 2004;6:193-201
29. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999;60(suppl 20):9-15
30. Keller MB, Hanks DL. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995;56(suppl 6):22-29
31. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005;66(suppl 8):22-29
32. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-1132
33. Thase ME. Comparison between seasonal affective disorder and other forms of recurrent depression. In: Rosenthal NE, Blehar MC, eds. Seasonal Affective Disorders & Phototherapy. New York, NY: Guilford Press; 1989:64-78
34. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005;162:656-662
35. Miller AL. Epidemiology, etiology, and natural treatment of seasonal effective disorder. Altern Med Rev 2005;10:5-13
36. Lam RW, Gorman CP, Michalon M, et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995;152:1765-1770
37. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006;6:1249-1265
38. Lam RW, Levitt AJ, Levitan RD, et al. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 2006;163:805-812
39. Ruhrmann S, Kasper S, Hawellek B, et al. Effects of fluoxetine versus bright light in the treatment of seasonal disorder. Psychol Med 1998;28:923-933
40. Murray G, Michalak EE, Levitt AJ, et al. O sweet spot where art thou? light treatment of seasonal affective disorder and the circadian time of sleep. J Affect Disord 2006;90:227-231
41. Swiecicki L, Szafranski T. Side effects after phototherapy implementation in addition to fluoxetine or sertraline treatment: a report of two cases. World J Biol Psychiatry 2002;2:109-111
42. Partonen T, Lonnqvist J. Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 1996;41:93-99
43. Cohen LS, Nonacs RM, Bailey JW, et al. Relapse of depression during pregnancy following antidepressant discontinuation: a preliminary prospective study. Arch Womens Ment Health 2004;7:217-221
44. Cohen LS, Altshuler LL, Stowe ZN, et al. Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment: a preliminary retrospective study. Psychother Psychosom 2004;73:255-258
45. Mian AI. Depression in pregnancy and the postpartum period: balancing adverse effects of untreated illness with treatment risks. J Psychiatr Pract 2005;11:389-396
46. Einarson A. The safety of psychotropic drug use during pregnancy: a review. Med Gen Med 2005;7:3
47. Patkar AA, Bilal L, Masand PS. Pharmacotherapy of depression in pregnancy. Ann Clin Psychiatry 2004;16:87-100
48. Nonacs R, Cohen LS. Depression during pregnancy: diagnosis and treatment options. J Clin Psychiatry 2002;63(suppl 7):24-30
49. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159:1889-1895
50. Serotonin reuptake inhibitor antidepressants and pregnancy: many unanswered questions. Prescrire Int 1999;8:157-159
51. Goldberg HL. Psychotropic drugs in pregnancy and lactation. Int J Psychiatry Med 1994;24:129-147
52. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-587
53. Blier P. Pregnancy, depression, antidepressants and breast-feeding. J Psychiatry Neurosci 2006;31:226-228
54. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-487
55. Einarson A, Koren G. Counseling women treated with paroxetine: concern about cardiac malformations. Can Fam Physician 2006;52:593-594
56. Bairy KL, Madhyastha S, Ashok KP, et al. Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2006;79:1-11
57. Hirschfeld MA. Clinical importance of long-term antidepressant treatment. Br J Psychiatry 2001;179:S4-S8
58. Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and Imipramine in the prophylaxis of unipolar and bipolar II illness. Arch Gen Psychiatry 1982;39:1065-1069
59. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, Imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-1104
60. Robinson DS, Lerfald SC, Bennett B, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 1991;27:31-39
61. Old Age Depression Interest Group. How long should the elderly take antidepressants? a double-blind placebo-controlled study of continuation/ prophylaxis therapy with dothiepin. Br J Psychiatry 1993;162:175-182
62. Kocsis JH, Friedman RA, Markowitz JC, et al. Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry 1996;53:769-774
63. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Am J Psychiatry 1998;13:55-62
64. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998;280:1665-1672
65. Keller MK, Yan B, Dunner D, et al. Recurrence prevention: efficacy of two years of maintenance treatment with venlafaxine XR in patients with recurrent unipolar major depression. In: New Abstracts. Presented at the 159th annual meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada.NR528
66. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-1099
67. Kupfer DF, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773
68. Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001;178:304-310
69. Lepine JP, Callaird V, Bisserbe JC, et al. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004;161:836-842
70. Mavissakalian MR, Perel JM, de Groot C. Imipramine treatment of panic disorder with agoraphobia: the second time around. J Psychiatr Res 1993;27:61-68
71. Fava M, Schmidt ME, Zhang S, et al. Treatment approaches to major depressive disorder relapse, part 2: reinitiation of antidepressant treatment. Psychother Psychosom 2002;71:195-199
72. Kupfer DJ, Frank E, Perel JM. The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry 1989;46:771-775
73. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressants from treatment initiation for depression. In: New Research Abstracts. Presented at the 159th annual meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada. NR468
74. Stewart JW, Tricamo E, McGrath PJ, et al. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Am J Psychiatry 1997;154:31-36
75. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR Publication 93-0551
76. Schulberg HC, Katon W, Simon GE, et al. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998;55:1121-1127
77. Robinson RL, Long SR, Chang S, et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm 2006;12:43-54
78. Kennedy S, McIntyre R, Fallu A, et al. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002;27:269-280
79. Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993;27:139-145
80. Schmidt ME, Fava M, Zhang S, et al. Treatment approaches to major depressive disorder relapse, part 1: dose increase. Psychother Psychosom 2002;71:190-194
81. Paykel ES. Cognitive-behavior therapy in relapse prevention in depression. Int J Neuropsychopharmacol 2006; E-pub ahead of print
82. Almeida AA, Lotufo Neto F. Cognitive-behavioral therapy in prevention of relapses and recurrences: a review. Rev Bras Psiquiatr 2003;25:239-244
83. Keller MB, McCullough JP, Klein DN, et al. Comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470
84. Kocsis JH, Rush AJ, Markowitz JC, et al. Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacol Bull 2003;37:73-87
85. Fava GA, Ruini C. Development and characteristics of a well-being psychotherapeutic strategy: well-being therapy. J Behav Ther Exp Psychiatry 2003;34:45-63
86. Fava GA, Rafanelli C, Cazzaro M, et al. Well-being therapy: a novel psychotherapeutic approach for residual symptoms of affective disorders. Psychol Med 1998;28:475-480
87. Ryff CD, Keyes CL. The structure of psychological well-being revisited. J Pers Soc Psychol 1995;69:719-727
88. Teasdale JD, Moore RG, Hayhurst H, et al. Metacognitive awareness and prevention of relapse in depression: empirical evidence.J Consult Clin Psychol 2002;70:275-287
89. Frank E, Kupfer DJ, Wagner EF, et al. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: contributing factors. Arch Gen Psychiatry 1991;48:1053-1059
90. McCrone P, Knapp M, Proudfoot J, et al. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 2004;185:55-62
91. Simon GE, Ludman EJ, Tutty S, et al. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. JAMA 2004;292:935-942
92. Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression. Arch Gen Psychiatry 2005;62:1007-1014
93. Kaltenthaler E, Brazier J, De Nigris E, et al. Computerized cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technol Assess 2006;33:1-186
94. Christensen H, Griffiths KM, Mackinnon AJ, et al. Online randomized controlled trial of brief and full cognitive behaviour therapy for depression. Psychol Med 2006; E-pub ahead of print
95. O'Kearney R, Gibson M, Christensen H, et al. Effects of a cognitive-behavioural internet program on depression, vulnerability to depression and stigma in a dolescent males: a school-based controlled trial. Cogn Behav Ther 2006;35:43-54
96. Frederikse M, Petrides G, Kellner C. Continuation and maintenance electroconvulsive therapy for the treatment of depressive illness: a response to the National Institute for Clinical Excellence report. J ECT 2006;22:13-17
97. Zajecka JM. Treating depression to remission. J Clin Psychiatry 2003;64(suppl 15):7-12
98. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006;63:1337-1344
99. van den Broek WW, Birkenhager TK, Mulder PG, et al. Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:263-268
100. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001;285:1299-1307
101. Davis LL, Frazier E, Husain MM, et al. Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. Am J Addict 2006;15:278-285
102. Thase ME, Ninan PT. New goals in the treatment of depression: moving toward recovery. Psychopharmacol Bull 2002;36(suppl 2):24-35
103. 2A receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 2002;302:983-991
104. Szabo ST, de Montigny C, Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2000;3:1-11
105. Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 2006; Epub ahead of print
106. Seager MA, Barth VN, Phebus LA, et al. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology (Berl) 2005;181:126-133
107. Solomon DA, Leon AC, Mueller TI, et al. Tachyphylaxis in unipolar major depression. J Clin Psychiatry 2005;66: 283-290
108. Lin EH, Von Korff M, Lin E, et al. The role of the primary care physician in patient's adherence to antidepressant therapy. Med Care 1995;33:67-74
109. Russell JM, Berndt ER, Miceli R, et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care 1999;5:597-606
110. Hirschfeld RMA. Long-term side effects of SSRIs: sexual dysfunction and weight gain. J Clin Psychiatry 2003;64(suppl 18):20-24
111. Craft LL, Perna FM. The benefits of exercise for the clinically depressed. Prim Care Companion J Clin Psychiatry 2004;6:104-111
112. van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci 1999;2:266-270
113. van Praag H, Christie BR, Sejnowski TJ, et al. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad USA 1999;96:13427-13431
114. Keller MB, Hirschfeld RM, Demyttenare K, et al. Optimizing outcomes in depression: focus on antidepressant treatment compliance. Int Clin Psychopharmacol 2002;17:265-271
115. Keller MB. Rationale and options for the long-term treatment of depression. Hum Psychopharmacol 2002;17(suppl 1):S43-S46
116. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
117. Pfizer Incorporated. Patient Health Questionnaire (PHQ-9). Available at: http://www.pfizer.com/pfizer/phq-9/index.jsp. Accessed Nov 7, 2006
118. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-583